share_log

AbbVie | DEF 14A: Definitive information statements

AbbVie | DEF 14A: Definitive information statements

艾伯维公司 | DEF 14A：股东委托书决议
美股sec公告 ·  03/18 16:23
Moomoo AI 已提取核心信息
AbbVie Inc. (AbbVie) has announced its 2024 Annual Meeting of Stockholders to be held virtually on May 3, 2024. The meeting will invite stockholders to vote on the election of five directors, the ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2024, advisory votes on executive compensation and the frequency of future stockholder advisory votes on executive compensation, and a management proposal to eliminate supermajority voting. Additionally, three stockholder proposals will be considered if properly presented. The meeting will also address any other matters that may properly come before it, including three stockholder proposals if presented. Stockholders as of the record date, March 4, 2024, are entitled to notice of and to vote at the meeting. AbbVie's board recommends voting for the election of the nominated directors, for the ratification of Ernst & Young LLP, for the approval of named executive officers' compensation, for annual advisory approvals of executive compensation, for the management proposal to eliminate supermajority voting, and against each of the stockholder proposals.
AbbVie Inc. (AbbVie) has announced its 2024 Annual Meeting of Stockholders to be held virtually on May 3, 2024. The meeting will invite stockholders to vote on the election of five directors, the ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2024, advisory votes on executive compensation and the frequency of future stockholder advisory votes on executive compensation, and a management proposal to eliminate supermajority voting. Additionally, three stockholder proposals will be considered if properly presented. The meeting will also address any other matters that may properly come before it, including three stockholder proposals if presented. Stockholders as of the record date, March 4, 2024, are entitled to notice of and to vote at the meeting. AbbVie's board recommends voting for the election of the nominated directors, for the ratification of Ernst & Young LLP, for the approval of named executive officers' compensation, for annual advisory approvals of executive compensation, for the management proposal to eliminate supermajority voting, and against each of the stockholder proposals.
艾伯维公司（AbbVie）宣布其2024年年度股东大会将于2024年5月3日虚拟举行。会议将邀请股东就五名董事的选举、批准安永会计师事务所作为艾伯维2024年独立注册会计师事务所、就高管薪酬和未来股东就高管薪酬进行咨询投票的频率以及取消绝大多数投票的管理层提案进行投票。此外，如果提交得当，将考虑三份股东提案。会议还将讨论可能恰当提出的任何其他问题，包括三份股东提案（如果提出）。截至创纪录的日期，即2024年3月4日，股东有权获得会议通知并在会议上投票。艾伯维董事会建议投票选举提名董事，批准安永会计师事务所，批准指定执行官的薪酬，对高管薪酬的年度咨询批准，管理层取消绝大多数投票的提议，反对每项股东提案。
艾伯维公司（AbbVie）宣布其2024年年度股东大会将于2024年5月3日虚拟举行。会议将邀请股东就五名董事的选举、批准安永会计师事务所作为艾伯维2024年独立注册会计师事务所、就高管薪酬和未来股东就高管薪酬进行咨询投票的频率以及取消绝大多数投票的管理层提案进行投票。此外，如果提交得当，将考虑三份股东提案。会议还将讨论可能恰当提出的任何其他问题，包括三份股东提案（如果提出）。截至创纪录的日期，即2024年3月4日，股东有权获得会议通知并在会议上投票。艾伯维董事会建议投票选举提名董事，批准安永会计师事务所，批准指定执行官的薪酬，对高管薪酬的年度咨询批准，管理层取消绝大多数投票的提议，反对每项股东提案。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息